Fruquintinib (Fruzaqla)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses fruquintinib (Fruzaqla),1 mg and 5 mg, oral capsules. Indication: For the treatment of adult patients with metastatic colorectal cancer who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF drug, an anti-EGFR drug (if RAS wild-type), and either trifluridine-tipiracil or regorafenib.